Herein we discuss JAK2 inhibitor persistence and link numerous studies that use disparate approaches yet converge on highlighting a potential critical role for the MEK/ERK pathway in the persistent survival of MPN-driving cells during chronic JAK2 inhibitor therapy. Here, MAP2K7 is linked to myeloproliferative disorder.